Hot biotech startups are attracting increased venture funding, and venture investors are ensuring a slot in the financing of these types of companies by starting the company themselves, Brian Gormley reports for Dow Jones VentureWire. The latest venture firm to do so is SR One, the venture arm of GlaxoSmithKline PLC.GSK.LN +1.16% The group, which invests in medical technologies, has added an entrepreneur in residence to its Cambridge, Mass., offices and has seeded its first startup through the effort, a company formed to develop drugs for cancer and inflammatory diseases. The firm’s launch of its own company comes after 30 years of funding existing companies.
{iframe}http://blogs.wsj.com/venturecapital/2015/11/23/the-daily-startup-sr-one-launches-startup-as-biotech-vcs-move-upstream/{/iframe}